Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 10, 2020
Reporting Period: Second fiscal quarter ended June 30, 2020, and the first half of 2020.
Key Financial Metrics
The filing serves as a notification of the release of financial results and does not contain specific numerical data within the text provided. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained in the attached press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2), which are incorporated by reference but not detailed in this summary text.
Material Changes
No specific material changes or comparative financial data are disclosed in the body of this 8-K filing. The document solely announces the availability of the Q2 and first-half 2020 results.
Guidance, Outlook, and Risks
- Disclosure: The filing includes a Regulation FD disclosure regarding a corporate presentation used for industry conferences (Exhibit 99.2).
- Disclaimer: The Company explicitly disclaims any obligation to correct or update the information in the corporate presentation in the future.
- Legal Status: The press release and presentation are furnished, not "filed," for purposes of Section 18 of the Exchange Act, and are not subject to the liabilities of that section unless expressly incorporated by reference in other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 and H1 2020 revenue, net income, and cash flow figures.
- Examine Exhibit 99.2 (Corporate Presentation) for management's outlook and strategic updates.
- Verify the company's status as an Emerging Growth Company (indicated as checked in the filing) and its implications for financial reporting standards.
- Confirm the trading symbol ORGO on the Nasdaq Capital Market.